Cobenfy (KarXT) received FDA approval as a groundbreaking antipsychotic targeting muscarinic acetylcholine receptors, diverging from traditional dopamine-focused treatments.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing
From Cobenfy to Emraclidine: the muscarinic path to safer antipsychotics
